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Abstract: Atherosclerosis is readily observed in areas where disturbed flow is formed, while the atheroprotective region is 
found in areas with steady laminar fl  ow (L-fl  ow). It has been established that L-fl  ow protects endothelial cells against endothelial 
dysfunction, including apoptosis and infl  ammation. It has also been reported that extracellular signal-regulated kinase 5 (ERK5) 
regulated endothelial integrity and protected endothelial cells from vascular dysfunction and disease under L-fl  ow. However, the 
molecular mechanism by which L-fl  ow-induced ERK5 activation inhibits endothelial apoptosis has not yet been determined. 
Transcription factor p53 is a major pro-apoptotic factor which contributes to apoptosis in various cell types. In this study, we 
found that 15-deoxy-Δ(12,14)-prostaglandin J2 induced p53 expression and that endothelial apoptosis was reduced under the 
L-fl  ow condition. Th   is anti-apoptotic response was reversed by the biochemical inhibition of ERK5 activation. It was also found 
that activation of ERK5 protected endothelial apoptosis in a C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase-
dependent manner. Moreover, molecular interaction between ERK5-CHIP and p53 ubiquitination were addressed with a CHIP 
ubiquitin ligase activity assay. Taken together, our data suggest that the ERK5-CHIP signal module elicited by L-fl  ow plays an 
important role in the anti-apoptotic mechanism in endothelial cells.
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[3]. Atheroprotective regions contain high, unidirectional 
and steady laminar flow (L-flow) while atheroprone re-
gions develop in low and disturbed flow areas [4]. The 
de  velop  mental process of atherosclerosis can be initiated 
by endothelial dysfunction, which includes activation of 
inflammatory responses and compromised barrier func-
tion due to endothelial apoptosis [5]. Manifestations of dys-
functional endothelial cells (ECs) were readily observed in 
certain areas of the arterial tree, while endothelial apoptosis 
was found to be much lower in legions exposed to L-fl  ow [6]. 
Many atheroprotective molecules are regulated in response to 
L-fl  ow [7]. However, what is lacking in current research is a 
plausible mechanistic relationship between L-fl  ow-mediated 
anti-apoptotic effects and any of the known regulators of 
Introduction
Atherosclerosis is a localized vascular disease characterized 
by the accumulation of lipids, leukocytes, and fibrous 
elements that go on to form arterial plaques [1, 2]. It has 
been well established that arterial plaque develops in certain 
areas such as bifurcations and curvatures, which has been 
proven by examining differences in blood flow dynamics Anat Cell Biol 2011;44:265-273 Jae Hyang Lim and Chang-Hoon Woo 266
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endothelial apoptosis that play a role in accelerating athero-
sclerosis formation.
Extracellular signal-regulated kinase 5 (ERK5) is one of 
major modulator in L-fl  ow-mediated cytoprotective responses 
in ECs. ERK5 belongs to the mitogen activated protein 
kinase (MAPK) family, which has dual phosphorylation sites 
characterized by a TEY motif. MAPK/ERK kinase 5 (MEK5) 
phosphorylates the TEY motif and activates ERK5 kinase 
activity. In contrast to ERK1/2, ERK5 has unique trans-
activation domain, suggesting that its regulation and function 
may be different from ERK1/2 [8, 9]. Like many MAPK 
family members, ERK5 plays a signifi  cant role in cell growth 
and diff    erentiation, although emerging evidence suggests that 
it has unique functional characteristics. Th   e redox activation 
of ERK5 has been documented as having an anti-apoptotic 
effect [10] and it was found that ERK5 knockout mice had 
impaired vascular development due to endothelial apoptosis 
[11], suggesting that ERK5 is an important regulator in endo-
thelial survival. It has been reported that ERK5 is involved 
in the cytoprotective effect that occurs in ECs in res  ponse 
to L-flow [12]. Endothelial apoptosis elicited by serum 
deprivation was markedly diminished under exposure to 
L-flow, but this protective response was reversed by trans-
ducing the dominant negative form of ERK5, indicating the 
cytoprotective role of ERK5 in L-flow signaling pathways. 
Garin et al. [13] reported that an L-fl  ow antagonized tumor 
necrosis factor alpha (TNFα)-induced endothelial apoptosis 
via inhibiting the caspase-dependent signaling pathway. Th  ese 
results implied that ERK5 acts as a key upstream molecule in 
L-flow-mediated anti-apoptotic responses via inhibiting the 
caspase-dependent pro-apoptotic pathway.
15-deoxy-Δ(12,14)-prostaglandin J2 (15d-PGJ2) is a mem-
ber of the cyclopentenone prostaglandins and is synthesized 
by cyclooxygenase pathways in various cell types. Because of 
the strong relationship between cyclooxygenase-dependent 
inflammatory responses and vascular inflam  mation, its 
lipid mediators might be involved in infl  ammatory vascular 
diseases, including athero  sclerosis. For instance, oxi  dized 
low-density lipoprotein (LDL) increases the intra  cellular 
level of 15d-PGJ2 in a cyclooxygenase-dependent man  ner. In 
addition, expression of Cox-2, oxidized LDL, and 15d-PGJ2 
were induced in atherosclerotic lession of ApoE
-/- 
mice [14]. Unlike other prostaglandins, 15d-PGJ2
 has no 
corresponding receptors on the cell surface. 15d-PGJ2 can 
be actively transported into cells and acts through direct 
interactions with its selective nuclear targets, including 
the nuclear transcriptional factor peroxisome proliferator-
activated receptor gamma (PPARγ  ) [15]. Interestingly, its 
cyclopentenone moiety provides an electrophilic carbon 
that mediates covalent modification with nucleophiles 
such as the free sulfhydryls of glutathione or the cysteine 
residues in target proteins [16]. These results suggest that 
15d-PGJ2 is not only a ligand of PPARγ, but also an inducer 
of covalent modifications of cellular target proteins, and is 
regulated in a PPARγ-independent manner. Several studies 
have demonstrated that 15d-PGJ2 induced apoptosis in ECs 
as well as in various cancer cell lines. Some of these sug-
gested that 15d-PGJ2-mediated apoptosis was regulated 
through the activation of PPARγ [17, 18]. However, recent 
re  ports have indicated that 15d-PGJ2-induced endothelial 
apoptosis is independent on PPARγ [19, 20]. For example, 
many of proapoptotic signal pathways induced by 15d-PGJ2 
have been shown to be independent of PPARγ in cancer 
cell lines. Although the involvement of PPARγ in 15d-PGJ2-
induced endothelial apoptosis is yet to be determined, p53 is 
a well established proapoptotic target in 15d-PGJ2-induced 
endothelial apoptosis [18, 21]. Ho et al. [22] reported that 
15d-PGJ2 induced endothelial apoptosis via stabilizing p53 
[22], suggesting the possible involvement of a ubiquitin-de-
pen  dent proteasome pathway. Th   e protein stability of p53 was 
mainly regulated by E3 ubiquitin ligase, including a mouse 
double minute 2 homolog (MDM2) and the C terminus 
of Hsc70-interacting protein (CHIP) [23-25]. Recently, we 
found that ERK5 activation of CHIP ubiquitin ligase activity 
protected cardiomyocytes via CHIP-mediated ubiquitination 
and degradation of the inducible cAMP early repressor 
[26]. Clearly, p53 expression regulates 15d-PGJ2-induced 
endothelial apoptosis, but the molecular mechanism by 
which L-fl  ow activation of ERK5 downregulates p53 protein 
expression via the ubiquitin-proteasome pathway remains 
largely unknown.
In this study, we found that ERK5 regulated L-flow-me-
diated anti-apoptotic responses in ECs. In addition, we 
discovered that ERK5 activation protects ECs from 15d- 
PGJ2-induced endothelial apoptosis via CHIP-mediated p53 
ubiquitination. Thus, these data demonstrate that L-flow-
mediated ERK5-CHIP signal cascade may play a critical role 
of anti-apoptotic responses. ERK5 induces CHIP-mediated p53 ubiquitination 
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Materials and Methods
Reagents and antibodies
15d-PGJ2 was purchased from Cayman (Ann Arbor, 
MI, USA). BIX 02189, a specific inhibitor of MEK5, was 
purchased from Selleck Chemicals (Houston, TX, USA). 
MTT reagents, H2O2 and DMSO, were purchased from Sigma 
(St. Louis, MO, USA). Antibodies were purchased from the 
following vendors: cleaved caspase 3 and phospho-ERK5 (Cell 
Signaling Technology, Danvers, MA, USA); tubulin (Sigma); 
poly (ADP-ribose) polymerase (PARP), CHIP, and p53 (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA).
Cell culture and laminar fl  ow
Human umbilical vein endothelial cells (HUVECs) were 
grown on 0.2% gelatin coated dish using an endothelial 
growth medium LSGS (Cascade Biologics, Portland, OR, 
USA) and 5% fetal bovine serum. Confluent HUVECs cul-
tured in 100 mm dishes were exposed to laminar flow (12 
dynes/cm
2) unidirectional fl  ow for 24 hours using a cone fl  ow 
system with 5% CO2 and at 37
oC, as described previously [27]. 
Transfection of the siRNAs and transduction of ade-
no viral  vectors
Small interfering RNAs against human p53 and CHIP 
were purchased from Santa Cruz Biotechnology (sc-29435 
and sc-43555, respectively). For our transient expression 
experiments, HUVECs were transiently transfected with 
100 pM of con  trol RNA or specific siRNAs against p53 or 
CHIP and using Lipofectamine 2000 reagent (#11668-019, 
Invitrogen, Carlsbad, CA, USA) following manufacturer 
protocols. A non-specifi  c control siRNA from Invitrogen was 
used as a negative control. The adenoviral vector encoding 
consti  tutively active form of MEK5α (Ad-CA-MEK5α) was 
described in a previous report [28].
Western blot analysis and Immuno  pre  ci  pitation 
analysis
HUVECs were lysed and extracts were incubated on 
ice for 15 minutes and then centrifuged (15,000 g for 
15 minutes at 4
oC). The concentrations in samples were 
determined using a Bradford assay. Primary antibodies were 
used to detect respective proteins, and visualized by using 
enhanced chemiluminescence detection reagents (Amersham 
Pharmacia Biotech) according to the manufacturer’s instruc-
tions. To conduct Immunoprecipitation analysis, cell 
lysates were incubated with an anti-CHIP antibody (Santa 
Cruz Biotechnology) or an anti-p53 antibody (Santa Cruz 
Biotechnology) overnight at 4°C as we described in a previous 
report [26].
  Quantitative real time reverse transcriptase-poly-
meratse chain reaction (RT-PCR)
To analyze mRNA expression of p53, a quantitative 
real time RT-PCR was performed. Briefly, the total RNA 
was isolated by TRIzol reagent (Invitrogen) and then a 
reverse transcription reaction was conducted by using Taq-
Man reverse transcription reagents (Applied Biosystems, 
Carlsbad, CA, USA), following the manufacturer’s instruc-
tions. Quantitative real time RT-PCR was conducted 
using 1 μl of template cDNA and Power SYBR Green 
(Applied Biosystems). Quantification was carried out 
using the efficiency-corrected ΔΔCq method. The specific 
oligonucleotide sequences for target genes were the following: 
TP53 (p53) forward 5'-GCCTGAGGTTGGCTCTGA-3' 
and reverse 5'-GTGGTGAGGCTCCCCTTT-3', glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) forward 
5'-GGAGCCAAAAGGGTCATCAT-3' and reverse 5'- 
GTGATGGCATGGACTGTGGT-3'.
In vitro ubiquitination assay with GST-p53
Ubiquitination activity was determined by in vitro ubi-
qui  tination assay, using GST-fused p53 recombinant pro  tein 
as a substrate (Ubiquitin-Protein Conjugation kit, Boston-
Biochem, Cambridge, MA, USA) as described previously 
[26]. Briefl  y, the lysates were applied for Immunoprecipitation 
analysis with an anti-CHIP antibody. Immunoprecipitated 
CHIP was incubated with recombinant proteins, including 
ubiquitin and an E1/E2 enzyme mixture, in energy buffer 
for 60 minutes at 37
oC. Th   e reaction was stopped by adding 
sodium dodecyl sulfate loading buff  er and then followed by 
immunoblotting with an anti-ubiquitin antibody. 
MTT assay
HUVECs were exposed to 10 μM of 15d-PGJ2 for 6 hours 
and then further incubated with MTT reagent for 2 hours in 
a 37
oC incubator. Precipitants were washed with phosphate 
buff  ered saline and eluted by adding a 500 μl mixture solution 
of DMSO and absolute ethanol (1 : 1). Cell viability was 
then measured by microplate reader (BIO-RAD, Hercules, 
CA, USA) at 570 nm, as described in a previous study [29].   Anat Cell Biol 2011;44:265-273 Jae Hyang Lim and Chang-Hoon Woo 268
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Statistical analysis
Data are reported as the mean±SD using Student’s t-test-
ing. A probability value of <0.05 was considered as signi  fi  cant. 
P-values of less than 0.01 are indicated by *.
Results
 L aminar  fl  ow inhibits 15d-PGJ2-induced endothelial 
apoptosis
We examined whether L-fl  ow protects ECs from 15d-PGJ2-
induced apoptosis. Confl  uent HUVECs were incubated under 
the L-flow (12 dynes/cm
2) or static condition for 24 hours 
and then followed by exposure to 10 μM PGJ2 for 8 hours. 
As shown in Fig. 1A, L-flow inhibited PARP cleavage and 
caspase 3 cleavage in response to 15d-PGJ2. In addition to the 
protein expression of proapoptotic molecules, we determined 
cell viability by using MTT assay. Treatment of 15d-PGJ2 
significantly reduced cell viability, but this reduction was 
completely reversed under the L-flow condition (Fig. 1B). 
Consistent with the viability assay results, we observed the 
same tendency with regards to morphological changes under 
control 15d-PGJ2, and 15d-PGJ2 under L-fl  ow conditions (Fig. 
1C-E). These results suggest that L-flow protects HUVECs 
from 15d-PGJ2-induced apoptosis.
L-fl  ow inhibits 15d-PGJ2-induced endothelial apopto-
sis via p53 downregulation
To examine the involvement of p53 in L-flow-mediated 
cytoprotective responses against 15d-PGJ2, we examined 
p53 protein expression with the same condition. Western 
blot analysis showed that 15d-PGJ2-induced p53 protein 
expression was markedly reduced in HUVECs cultured 
under L-flow (Fig. 2A). To assess the role of p53 induction 
Fig. 1. Laminar fl  ow inhibits 15d-PGJ2-induced endothelial apoptosis. Confl  uent HUVECs were cultured under L-fl  ow (12 dyne/cm
2) or a static 
condition for 24 h. Cells were then exposed to 10 μM 15d-PGJ2 for 8 h. (A) Cell lysates were applied for immunoblotting with anti-PARP, anti-
cleaved caspase 3, and anti-tubulin antibodies. Data are representative of results from three separate experiments. (B) Cell viability was determined 
by using MTT assay. Data are expressed as the mean±SD from three independent experiments. *P<0.01. Morphological changes of HUVECs 
were examined by microscopy under control (C), 15d-PGJ2 (D), or 15d-PGJ2 under L-fl  ow (E). Scale bars=100 μm (C-E). 15d-PGJ2, 15-deoxy-
Δ(12,14)-prostaglandin J2; HUVECs, human umbilical vein endothelial cells; L-fl  ow, steady laminar fl  ow; PARP, poly (ADP-ribose) polymerase; 
OD, optical density.ERK5 induces CHIP-mediated p53 ubiquitination 
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in 15d-PGJ2-induced endothelial apoptosis, we performed 
genetic depletion of p53 with siRNA against human p53. 
As shown in Fig. 2B, depletion of p53 reduced the level of 
cleaved caspase 3 in response to 15d-PGJ2. In line with this 
observation, we found that 15d-PGJ2-mediated reduction 
of cell viability was reversed by the depletion of p53 (Fig. 
2C). Th   ese experimental results imply that L-fl  ow-mediated 
reduction of p53 might be a key part of the protection of ECs 
from 15d-PGJ2-induced apoptosis.
Fig. 2. L-flow inhibits 15d-PGJ2-in  duced endothelial apoptosis via p53 down  regulation. (A) HUVECs were exposed to L-flow followed by 
treatment with 15d-PGJ2 for 8 h. Protein expression was determined by Western blotting using anti-p53 and anti-tu  bulin antibodies. (B) HUVECs 
were transfected with either control or p53 siRNA (si-p53) for two days. Cells were then exposed to 10 μM 15d-PGJ2 for 8 h. Th   e expression of 
cleaved caspase 3, p53, and tubulin was detected by Western blotting with the respective antibodies. (C) Cell viability was determined by MTT 
assay. Data are expressed as the mean±SD from three independent experiments. *P<0.01. L-flow, steady laminar flow; 15d-PGJ2, 15-deoxy-
Δ(12,14)-prostaglandin J2; HUVECs, human umbilical vein endothelial cells.
Fig. 3. Th  e  ERK5-CHIP signal module protects endothelial apoptosis in res  ponse to 15d-PGJ2. (A) HUVECs were pretreated with DMSO or 10 
μM BIX02189, a specifi  c inhibitor of MEK5, before applying L-fl  ow. Cells were then exposed to 10 μM 15d-PGJ2 for 8 h. Th   e protein expression 
of p53, phosphorylated ERK5, and tubulin were determined by immunoblotting with specifi  c antibodies. (B) HUVECs were transfected with 
siRNA against human CHIP (si-CHIP) or control RNA and then followed by transducing the adenovirus encoding con  stitutively active form of 
MEK5 alpha (Ad-CA-MEK5α). Cells were then exposed to 10 μM 15d-PGJ2 for 8 h. Cell lysates were subjected to Western blot analysis with 
anti-cleaved caspase 3, anti-phospho ERK5, anti-CHIP, and anti-tubulin antibodies. (C) Cell viability was determined by MTT assay. Data are 
expressed as the mean±SD from three independent experiments. *P<0.01. ERK5, extracellular signal-regulated ki  nase 5; CHIP, C terminus of 
Hsc70-interacting protein; 15d-PGJ2, 15-deoxy-Δ(12,14)-prostaglandin J2; HUVEC, human umbilical vein endothelial cells; OD, optical density; 
NS, non-signifi  cant.Anat Cell Biol 2011;44:265-273 Jae Hyang Lim and Chang-Hoon Woo 270
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ERK5-CHIP signal module protects endothelial apop-
tosis induced by 15d-PGJ2
Next, we assessed the role of ERK5 in regulating p53 expres-
sion induced by 15d-PGJ2 with biochemical inhibition. The 
pretreatment of a BIX02189 compound, which is a specific 
inhibitor of MEK5, suppressed L-flow-mediated reduction 
of p53 expression in response to 15d-PGJ2, suggesting the 
potential role of ERK5 in the regulation of p53 expression 
(Fig. 3A). To confi  rm the specifi  c role of ERK5 activation in 
endothelial apoptosis, we utilized an adenoviral system to 
express the constitutively active form of MEK5 alpha (Ad-CA-
MEK5α). As shown in Fig. 3B, the level of cleaved caspase 3 
was remarkably reduced by overexpressing CA-MEK5α. Th  is 
reduction of cleaved caspase 3 was reversed by the depletion 
of CHIP ubiquitin ligase with siRNA against human CHIP. 
Additionally, we found that a similar pattern was observed 
using a cell viability assay (Fig. 3C). Along with previous 
evidence that has suggested that CHIP is a known ubiquitin 
ligase of p53 and that ERK5 activates the ubiquitin ligase 
activity of CHIP, our results sugges that L-fl  ow activation of 
ERK5 inhibits 15d-PGJ2-induced endothelial apoptosis via 
CHIP-mediated p53 ubiquitination.
ERK5 activation induces p53 ubiquitination via in-
creasing CHIP ubiquitin ligase activity
To determine the involvement of transcriptional regulation 
of p53 by ERK5, the mRNA level of p53 was determined by 
quantitative RT-PCR. Neither 15d-PGJ2 treatment nor Ad-
CA-MEK5α transduction resulted in any signifi  cant changes 
(Fig. 4A). This may be because p53 can be regulated by 
ubiquitination at the post-translation level. As shown in Fig. 
4B, p53 ubiquitination was increased by transduction of Ad-
CA-MEK5α, suggesting the involvement of post-translation 
modification in ERK5-mediated p53 downregulation (Fig. 
4B). To address whether ERK5 activation induced p53 ubi-
qui  tination via increasing the ubiquitin ligase activity of 
CHIP, we utilized BIX02189 in the presence or absence of 
Ad-CA-MEK5α, and then detected CHIP ubiquitin ligase 
activity using in vitro ubiquitination assay with GST-fused 
p53 recombinant protein as substrate. As shown in Fig. 4, 
transduction with Ad-CA-MEK5α markedly increased the 
level of p53 ubiquitination, which was inhibited by bio-
Fig. 4. ERK5 activation induces p53 ubiquitination via increasing CHIP ubiquitin ligase activity. (A) Aft  er transduction with Ad-CA-MEK5α  
or the Ad-LacZ control, HUVECs were exposed to 15d-PGJ2 for 4 h. Th   e level of p53 mRNA was determined by using real time quantitative RT-
PCR as described in the Materials and Methods section. (B) Th   e endogenous level of p53 ubiquitination was determined by immunoprecipitation 
analysis with anti-p53 antibody, followed by immunoblotting with an anti-ubiquitin antibody. (C) CHIP ubiquitin ligase activity was determined 
by an in vitro ubiquitination assay kit (BostonBiochem) with a GST-fused p53 recombinant protein as a substrate. HUVECs were transduced with 
Ad-CA-MEK5α and then followed by treatment with 10 μM BIX02189. Cell lysates were applied for immunoprecipitation analysis with an anti-
CHIP antibody. Immunoprecipitated CHIP was incubated with recombinant proteins including ubiquitin and E1/E2 enzyme mixture, for 60 
min at 37
oC. CHIP ubiquitin ligase activity was determined by immunoblotting with an anti-ubiquitin antibody. Th   e protein amount of GST-p53 
and immunoprecipitated CHIP was detected by Western blot analysis with anti-p53 and anti-CHIP antibodies. Data are representative of three 
independent experiments. ERK5, extracellular signal-regulated kinase 5; CHIP, C terminus of Hsc70-interacting protein; Ad-CA-MEK5α, 
adenovirus encoding constitutively active form of MEK5 alpha; 15d-PGJ2, 15-deoxy-Δ(12,14)-prostaglandin J2; RT-PCR, reverse transcriptase-
polymeratse chain reaction; HUVEC, human umbilical vein endothelial cells; IP, immunoprecipitation; IB, immunoblot; NS, non-signifi  cant.ERK5 induces CHIP-mediated p53 ubiquitination 
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chemical inhibition of ERK5 with BIX02189. These re-
sults indicated that ERK5 activation reduced p53 protein 
expression via CHIP-mediated ubiquitination of p53.
Discussion
Th   e proapoptotic transcription factor p53 has been recog-
nized as a key regulator of cell fate, acting as a sensor for DNA 
damage. Recent studies have revealed that p53 is involved 
in cytotoxic cyclopentenone prostaglandin 15d-PGJ2-in-
duced apoptosis in ECs, but the molecular mechanism that 
contributes to endothelial apoptosis has only been partially 
understood. Particularly, the relationship between blood 
fl  ow dynamics-dependent anti-apoptotic responses and p53-
de  pendent apoptotic regulation remains to be determined. 
Our data demonstrated that L-fl  ow-induced ERK5 activation 
exerts cytoprotective responses via anti-apoptotic signaling 
pathways carried on p53 downregulation. In the present study, 
we provide evidence that L-flow inhibits 15d-PGJ2-induced 
endothelial apoptosis in both a p53- and ERK5-dependent 
manner (Fig. 1). Our results showed that L-flow-mediated 
reduction of p53 expression and endothelial apoptosis was 
reversed by BIX02189, which is a specifi  c inhibitor of MEK5 
(Fig. 2). In addition to L-fl  ow, overexpression of CA-MEK5α 
using an adenoviral system reduced 15d-PGJ2-induced endo-
thelial apoptosis, and this reduction of apoptosis was reversed 
by depletion of CHIP ubiquitin ligase (Fig. 3). Furthermore, 
transduction of Ad-CA-MEK5α increased the ubiquitin ligase 
activity of CHIP, which was determined by detecting p53 
ubiquitination (Fig. 4). Based on these results, we propose 
that the major molecular mechanism by which L-flow acti-
vation of ERK5 downregulates p53 protein expression is via 
increasing the CHIP-mediated ubiquitination of p53.  
Th   e regulation of apoptosis by p53 has been suggested to 
take place because of the activation of transcriptional acti-
vity, which in turn leads to the induction of proapoptotic 
genes, including B cell lymphoma/leukemia-2 (Bcl-2) family 
proteins [30]. However, recent studies have also revealed 
non-transcriptional pro-apoptotic activities. For instance, 
genotoxic stress induced not only p53-dependent gene expres-
sion but also the nuclear export of p53 [30, 31]. In a resting 
state, p53 is mainly located in the nucleus, but cytosolic p53 
directly interacts with the mitochondrial anti-apoptotic Bcl-2 
family proteins such as Bcl-xL and Bcl-2 [31]. It has been well 
accepted that p53 stability is regulated by ubiquitin ligases, 
including MDM2 and CHIP. Ubiquitin ligase-mediated 
poly  ubi  quitination decreases p53 protein expression via 
pro  teasomal degradation. Esser et al. [23] reported that p53 
interacted with the heat shock protein Hsp70, which is a 
key factor in CHIP-mediated protein ubiquitination and the 
proteasomal degradation of target proteins. Since Hsp70 was 
induced by 15d-PGJ2, induced Hsp70 might affect a triple 
complex consisting of Hsp70, p53, and CHIP. Carter et al. [32] 
proposed a possible molecular mechanism for p53 nuclear 
export and stabilization. In the condition of low level of 
MDM2, MDM2 causes monoubiquitination and subsequent 
sumoylation of p53, which leads to p53 nuclear export. It is 
particularly interesting that 15d-PGJ2 induces the nuclear 
export of p53 and increases binding affinity to prosurvival 
Bcl-2 family proteins.
We addressed the relationship between ERK5 activation 
and p53 downregulation in 15d-PGJ2-induced endothelial 
apoptosis. Here, we showed that L-flow reduced 15d-PGJ2-
induced p53 expression and subsequent endothelial apop-
tosis, suggesting that L-fl  ow aff  ected signaling events down-
stream of p53. Since EKR5 is a major regulator in L-flow-
mediated cytoprotective responses and that ERK5 activates 
CHIP ubiquitin ligase activity, it is relevant to note that ERK5 
activation downregulates p53 protein expression via CHIP-
mediated ubiquitination of p53. In agreement with this 
con  cept, ERK5 activation induced by transduction of Ad-
CA-MEK5α induced CHIP-dependent p53 ubiquitination, 
indicating that p53 is a substrate of CHIP and that p53 down-
regulation contributes to the L-fl  ow-mediated cytoprotective 
responses. It is not yet clear how ERK5 activation increases 
CHIP-mediated p53 ubiquitination. In our previous report, 
we showed that ERK5 bound to the C-terminus U-box do-
main of CHIP which is important for ubiquitinination acti-
vity, suggesting that ERK5 binding to CHIP may aff  ect CHIP 
enzyme activity through a conformational change [26]. Se-
veral apoptosis regulating molecules have been recognized 
as the target of ERK5 in endothelial apoptosis in response to 
L-flow. For example, Pi et al. [12] showed that L-flow acti-
vation of ERK5 induced phosphorylation of proapoptotic 
Bad, which contributes to the inhibition of endothelial 
apop    tosis. However, it was not proved whether ERK5 direc-
tly phosphorylate Bad or not. The same research group 
suggested that TNFα-induced c-jun kinase (JNK) activation 
was inhibited by the biochemical inhibition of ERK5 with 
BIX02188 [33]. Since apoptosis signal-regulating kinase 1 
(ASK1) is an upstream molecule of the JNK pathway and is Anat Cell Biol 2011;44:265-273 Jae Hyang Lim and Chang-Hoon Woo 272
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known to be a substrate to CHIP ubiquitin ligase, it is possible 
to speculate that ERK5 activation might affect the CHIP-
mediated downregulation of the ASK-JNK signaling pathway 
in L-fl  ow-mediated cytoprotective responses. 
In conclusion, we have identifi  ed ERK5 as a novel negative 
regulator of p53-depedent endothelial apoptosis in response 
to 15d-PGJ2. ERK5 activation exerts the downregulation of 
p53 and the inhibition of subsequent endothelial apoptosis in 
a CHIP-dependent manner. Additionally, the ERK5 activation 
of CHIP ubiquitin ligase was linked to L-flow-mediated EC 
protection from 15d-PGJ2-induced endothelial apoptosis. Our 
results suggest that the ERK5-CHIP signal module could be 
a potential target for pharmacological intervention that could 
prevent endothelial dysfunction-related vascular diseases, 
including atherosclerosis. 
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